<DOC>
	<DOCNO>NCT02333383</DOCNO>
	<brief_summary>This prospective mono-country , multi-center study Ankylosing Spondylitis ( AS ) subject treated Adalimumab . At least 200 subject enrol approximately 10 site . The baseline assessment perform prior first dose Adalimumab . Study visit conduct 12 , 28 , 36 52 week baseline . All subject one follow-up approximately 70 day last dose Adalimumab .</brief_summary>
	<brief_title>Observe Frequency Extra-Axial Symptoms Korean Ankylosing Spondylitis ( AS ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject must adult ≥19 year . Subject diagnose ankylose spondylitis ( AS ) accord 1984 modified New York criteria least 3 month . Subject active disease define Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) score ≥4 , despite treatment least 2 Nonsteroidal antiinflammatory drug ( NSAIDs ) DMARDs 3 month base Korea AS reimbursement guideline . Subject eligible adalimumab daily rheumatologic practice . Subject must provide write authorization form use personal and/or health data prior entry study . Female subject pregnant breast feeding . Subject applies contraindication antiTNF agent . Subject participate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) score</keyword>
	<keyword>EAMs</keyword>
	<keyword>Adalimumab</keyword>
</DOC>